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the Dominant intervention package. In part, this is because of the inefficiency of current 
practice in blood pressure and cholesterol lowering due to a preference for expensive drugs 
and the inadequate targeting of people at risk based on individual risk factor levels rather 
than absolute cardiovascular risk. Also, the taxation and regulation interventions in the 
Dominant intervention package reduce the need for preventive cardiovascular disease drugs 
which remain expensive even if prescribed most efficiently. 
 
Figure 1: Intervention costs, cost offsets and health gain with the package of Dominant (cost-saving) 
preventive interventions. 
 
Figure 2: Intervention costs, cost offsets and health gain with the package of Dominant (cost-saving) 
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Figure 2: Intervention costs, cost offsets and health gain with the package of Dominant (cost-saving) 
preventive interventions and current practice. 
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Figure 3: Intervention costs, cost offsets and health gain with the package of Dominant and Very 
Cost-Effective (0 to $10,000/DALY) preventive interventions: (a) including the Polypill; (b) including 
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Table 1: Dominant and Very Cost-Effective interventions 
Topic area Dominant interventions Very Cost-Effective interventions 
Alcohol • Volumetric tax 
• Tax increase 30% 
• Advertising bans 
• Raise minimum legal drinking age to 21 
• Brief alcohol intervention GP with or without 
telemarketing and support 
• Licensing controls 
Tobacco • Tax increase 30% (with or without 
indexation) 
• Cessation aids: varenicline, bupropion and 
nicotine replacement therapy 
Physical activity • Pedometers 
• Mass media 
• GP Green Prescription  
• Internet intervention 
Nutrition • Community fruit and vegetable intake 
promotion 
• Voluntary salt limits 
• Mandatory salt limits 
• Information mail-out, multiple re-tailored to 
promote fruit and vegetable intake 
Body mass • 10% tax on unhealthy food • Gastric banding for severe obesity 
Blood pressure 
and cholesterol 
• Community heart health program 
• Polypill $200 for >5% CVD risk 
• Low-dose diuretics >5% CVD risk 
• CCBs >10% CVD risk 
• ACE inhibitors >15% CVD risk  
• Polypill $200 to ages 55+ 
Mental disorders • Problem-solving post-suicide attempt 
• Treatment for individuals at ultra-high risk 
for psychosis 
• Screen and bibliotherapy to prevent adult and 
childhood depression  
• Screen and psychologist to prevent 
childhood/adolescent depression 
• Responsible media reporting for the reduction 
of suicide 
• Parenting intervention for the prevention of 
childhood anxiety disorders 
Osteoporosis  • Screen women aged 70+ and alendronate  
Hepatitis B • Vaccine and immunoglobulin to infants 
born to carrier or high-risk mothers 
• Universal infant vaccination 
 • High-risk infant vaccination  
 • Selective vaccination of infants with 
mothers from highly endemic countries 
 
Kidney disease • Proteinuria screen and ACE inhibitors for 
diabetics 
 
Oral health • Fluoridation drinking water, non-remote   




To aid priority setting in prevention, the Assessing Cost-Effectiveness in Prevention Project (ACE-Prevention) applies 
standardised evaluation methods to assess the cost-effectiveness of 100 to 150 preventive interventions, taking a health 
sector perspective. This information is intended to help decision-makers move resources from less efficient current 
practices to more efficient preventive action resulting in greater health gain for the same outlay.
Indigenous population results 
1.   Cardiovascular disease prevention 
2.   Diabetes prevention 
3.   Screening and early treatment of chronic kidney disease
Overall results 
1.   League table 
2.   Combined effects 
paMpHlets in tHis series 
Methods: 
A.   The ACE-Prevention project 
B.   ACE approach to priority setting 
C.   Key assumptions underlying the economic analysis 
D.   Interpretation of ACE-Prevention cost-effectiveness results 















14. Renal replacement therapy, screening and early treatment of chronic kidney disease
15. Salt
16. Suicide prevention
17. Tobacco 
